Discovery of Pyrazolo[1,5- a ]pyridine Derivatives as Potent and Selective PI3Kγ/δ Inhibitors
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c00817 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Chun Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Ch…. Hauptthemen laut MEDLINE: Pyridines, Phosphoinositide-3 Kinase Inhibitors, Pyrazoles, Class Ib Phosphatidylinositol 3-Kinase. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Hefei Institutes of Physical Science, Chinese Academy of Sciences, Youth Innovation Promotion Association of the Chinese Academy of Sciences, Major Science and Technology Projects in Anhui Province.
Abstract (Originalsprache)
PI3Kγ and PI3Kδ plays critical roles in exerting immunosuppression by targeting regulatory T cells and myeloid cells. Dual inhibition of PI3Kγ and PI3Kδ has emerged as a novel therapeutic strategy for cancer immunotherapy. We herein report a series of pyrazolopyridine derivatives with distinct scaffolds as potent and selective dual inhibitors of PI3Kγ and PI3Kδ. Among them, 20e (IHMT-PI3K-315) displays an IC50 value of 4.0 and 9.1 nM against PI3Kγ and PI3Kδ respectively in biochemical assays. Meanwhile, it potently inhibits PI3Kγ and PI3Kδ-mediated phosphorylation of AKT S473 with EC50 values of 0.028 and 0.013 μM in cellular assays. In addition, 20e exhibits a favorable selectivity profile in protein kinases at 1 μM. In bone marrow-derived macrophages (BMDM), 20e can repolarize the M2 phenotype to the M1 phenotype. In vivo, 20e demonstrates acceptable pharmacokinetic properties and suppresses tumor growth in a MC38 syngeneic mouse model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China.
- University of Science and Technology of China, Hefei, Anhui 230026, P. R. China.
- Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China.
- Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China.
- Primary Cell Engineering Joint Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China.
ORCID-Profile: Xiaofei Liang, Qingsong Liu, Jing Liu
Förderung
- Hefei Institutes of Physical Science, Chinese Academy of Sciences
- Youth Innovation Promotion Association of the Chinese Academy of Sciences
- Major Science and Technology Projects in Anhui Province
- National Natural Science Foundation of China
- Anhui Provincial Key Research and Development Plan
Zitieren
APA
Wang, C., Zou, F., Qi, Z., Liu, Q., Shen, L., Yuan, X., Deng, M., Wang, A., Wang, B., Wang, L., Liang, X., Liu, Q., & Liu, J. (2024). Discovery of Pyrazolo[1,5- a ]pyridine Derivatives as Potent and Selective PI3Kγ/δ Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00817
Vancouver
Wang C, Zou F, Qi Z, Liu Q, Shen L, Yuan X, et al. Discovery of Pyrazolo[1,5- a ]pyridine Derivatives as Potent and Selective PI3Kγ/δ Inhibitors. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00817
BibTeX
@article{Wang2024,
author = {Wang, Chun and Zou, Fengming and Qi, Ziping and Liu, Qingwang and Shen, Lijuan and Yuan, Xinyu and Deng, Maoqing and Wang, Aoli and Wang, Beilei and Wang, Li and Liang, Xiaofei and Liu, Qingsong and Liu, Jing},
title = {Discovery of Pyrazolo[1,5- a ]pyridine Derivatives as Potent and Selective PI3Kγ/δ Inhibitors},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c00817}
}
EUVIMED